-
DOJ Case Against Live Nation Is 'Weak,' Analysts Say: 'Separating Ticketmaster... Is Unlikely To Lower Ticket Prices'
Friday, May 24, 2024 - 1:14pm | 550Read More...The Department of Justice filed an antitrust lawsuit against Live Nation Entertainment (NYSE:LYV), which sent shares down during the week. Analysts react to the news and share what's ahead for the entertainment company. The LYV Analysts: Guggenheim analyst Curry Baker has a Buy rating and $128...
-
Analysts Praise Target's Q3 Results, Gross Margins, But Have Cautious Tone For Future: Retailer 'Facing The Largest Macro Headwinds'
Thursday, November 16, 2023 - 2:11pm | 859Read More...Retailer Target Corp (NYSE:TGT) reported third-quarter financial results that included revenue and earnings per share coming in ahead of estimates from analysts. Here's a look at what analysts are saying about the company after the report. The Target Analysts: Bank of America analyst Robert F....
-
Yelp Shares Lower As Facebook Could Get Into 'Professional Services'; Here's One Analyst's Take
Tuesday, December 15, 2015 - 4:25pm | 426Read More...Shares of Yelp Inc (NYSE: YELP) were trading down 8 percent on Tuesday afternoon. The decline seems to have been triggered by news about Facebook Inc (NASDAQ: FB)’s new Professional Services feature, which offers people the ability to find the best-rated businesses in a particular area...
-
Digital Ally Set For Its First Profitable Quarter Since 2013, Says Roth Capital
Tuesday, November 10, 2015 - 2:51pm | 335Read More...Digital Ally, Inc. (NASDAQ: DGLY) will announce its third-quarter financial results after the market closes on Wednesday. Ahead of the earnings call, Roth Capital Partners analyst William Gibson shared a preview of the results, assuring expectations of a profitable quarter. The firm reiterated a...
-
Energous Just Lost Its CCO; What You Need To Know (And Why It Is Still A Buy)
Tuesday, October 6, 2015 - 4:30pm | 354Read More...Energous Corp (NASDAQ: WATT)'s Chief Commercial Officer George Holmes resigned on Tuesday, to take a similar spot at a private, non-competitive company. After the event, Roth Capital reiterated a Buy rating and $15.00 price target on the stock. Shares of Energous were slightly down on...
-
Inuvo Could Hit 65% Earnings CAGR Through 2018: How To Play It
Tuesday, September 29, 2015 - 3:22pm | 306Read More...On Tuesday, Roth Capital initiated coverage on Inuvo Inc (NYSE: INUV) with a Buy rating and a $4.50 12-month price target. The firm’s thesis is based on the company’s potential to deliver earnings growth at a 65 percent CAGR over the next three years. Shares of Inuvo were up...
-
Roth Still Loves Galmed Pharma, Keeps $20 Price Target And 'Buy' Rating
Wednesday, July 8, 2015 - 9:26pm | 276Read More...Shares of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) fell 3.34 percent on Wednesday, after the company announced the “inlicensing of a companion diagnostic test candidate for the co-development with the company's drug Aramchol for the treatment of NASH," according to a new note from...
-
Analysts Weigh In On Amended Bluebird Bio/Celgene Deal
Thursday, June 4, 2015 - 11:53am | 355Read More...Bluebird bio Inc (NASDAQ: BLUE) and Celgene Corporation (NASDAQ: CELG) announced a restructuring of its CAR-T collaboration this week. Under the amended terms of the deal, the collaboration will focus on CAR-T cells that target the B-cell maturation antigen (BCMA). Celgene will also provide $25...
-
Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth
Tuesday, October 7, 2014 - 4:19pm | 264Read More...Sunesis Pharmaceuticals, Inc.'s (NASDAQ: SNSS) failed cancer drug vosaroxin offers no reason for investors to give up hope on other companies' potential cures, an analyst said Tuesday. Sunesis said Tuesday its vosaroxin drug for acute myeloid leukemia failed to show effectiveness in a...
